Our data showed a trend for a shorter RFS in PHF6 mut AML (8.0 vs. 19.0 months; p = 0.664), although there were no significant differences in RFS or remission duration, which was partly due to the relatively small sample size.
The control group with low RET-He also showed a trend toward decreased RET-He, with no significant difference (p = 0.674).
Nimbolide or doxorubicin treatment to HCC mice showed a trend in increased body weight from 28 th to 32 nd week ( P = 0.6781) (Figure 1B ).
Similarly, patients undergoing resection for mCRC showed a trend toward longer median OS in the low-risk group with the cut-off, P > 0.68 (Fig. 4 C), while no differences were found in the CCa group.
Kaplan–Meier survival analysis showed a trend for lower PFS in patients with MMRD-HGG than those in patients without MMRD-HGG ( p = 0.69, p = 0.64) (Fig. 6A, C ).
Compared to the control group, the L group showed a trend toward increased CAT activity ( P = 0.69), significantly elevated GSH content ( P < 0.05), and no significant changes in T-SOD or MDA activity/content ( P > 0.05).
Overall Vertical Height Changes (Point 1) The mean vertical height of the zenith point (point 1) showed a trend to negatively change slightly ( p = 0.692) from baseline to 6 months of −0.48 mm (±0.52), which corresponds to a recession of the mucosal margin of 0.48 mm.
A subgroup analysis of home HD patients showed adverse events were more likely among non-visual learners (OR 11.1; p=0.003), whereas PD patients showed a trend for more adverse events in non-visual learners (OR: 1.60; p=0.694).
Research results Our study showed a trend toward lower GI toxicities in patients with high MDSS at each timepoint (first evaluation: P = 0.7; second: P = 0, 52; and third: P =0.01).
Overall, results showed a trend toward an increase in IVI-guided PCI between 2022 and 2024 (15.6% vs 19.1%, P = 0.7).
Analysis by the subgroup showed a trend of increased risk of hypertension, without significant results, for bosutinib and dasatinib with an RR of 1.11 (95% CI; 0.64–1.93, I 2 = 25%, z = 0.39, p = 0.70) and 1.50 (95% CI; 0.89–2.54, I 2 = 0%, z = 1.52, p = 0.13), respectively.
In general, the DLSE in Hunan Province presented a pattern of “four weeks high, central low”, and showed a trend of continuous growth ( R n ̄ = 0.9999 > W p = 0.703 ).
In subgroup analysis of patients with blood eosinophil count ≥ 300 cells/μl, ICS use showed a trend to reduce the risk for exacerbation (IRR = 0.907, p = 0.708).
In parallel, SM07883-treated animals showed a trend toward reduced latencies (p = 0.71) and path lengths (p = 0.46) to locate the target hole in the Barnes maze, alongside increased exploratory velocity, but these effects were not statistically significant compared with RHI-V animals.
Long-term results showed a trend toward poorer prognosis in the BMI >30 group for laparotomy when comparing the four groups ( P = .711).
However, MOFA factor 2 showed a trend ( P = 0.72) towards differentiating white from beige adipocytes, driven primarily by H3K27me3 and H3K4me1 ( Figure 4 G–H).
Kaplan–Meier analyses charting the cumulative probability of recurrence of leukoplakia showed a trend that the high expression group of all four biomarkers by itself was associated with recurrence after surgical excisions (Ki-67; p = 0.72, p53; p = 0.27, p63; p = 0.11 and PDPN; p = 0.23; Fig. 3 ).
However, the combination of IV Monofer and ABT showed a trend towards increased mortality compared to ABT alone (HR 1.34, 95% CI [0.269–6.653], P = 0.7215).
Furthermore, Iba1 expression was associated with the presence of metastases ( p < 0.05), and, although not statistically significant, CD163 expression showed a trend ( p = 0.73).
In the NHANES, patients with active HBV showed a trend of worst survival; however, the difference between active HBV and past HBV infection did not reached a statistical difference ( P = 0.732, S2A Fig ).
Although we found no significant correlation between patient attributes (eg, BMI and resection weight) and complication rates, patients with larger tissue resections (≥1000 g) showed a trend toward slightly higher complication rates (29.2% versus 20.8%, P = 0.74).
Patients with nodal positivity showed a trend toward having more lymph nodes identified in the blinded preoperative imaging review (median = 2.5) compared to node-negative patients (median = 2.0, p = 0.74).
The Kaplan–Meier analysis showed a trend toward better OS ( P = 0.7401) in patients that experienced neither dose reduction nor dose delay (median OS not reached), followed by patients that experienced only dose delay (median OS not reached), than patients with only dose reduction (median OS = 124 months) and finally patients that experienced both dose reduction and dose delay (median OS = 92 months).
Imn the absence of cirrhosis, NASH-HCC patients showed a trend to an increased OS compared to non-NASH HCC patients (43.4 vs. 25 month, p = 0.748) (Figure 2 ).
5 μM Aβo), and [Ca 2+ ] i showed a trend towards a further decrease in cells pretreated with 5 μM G-15 at 65 s ( p = 0.749 vs. 5 μM Aβo + Est) ( Figure 9 C,D). 4.